Skip to main content
. 2024 Apr 22;39(6):1208–1221. doi: 10.1093/humrep/deae076

Figure 3.

Figure 3.

Dysmenorrhea and non-menstrual pelvic pain in women treated by placebo, 75 mg linzagolix daily or 200 mg linzagolix plus ABT, at 3 and 6 months. (A) Dysmenorrhea and non-menstrual pelvic pain at 3 months (mean ± 95% CI). Error bars represent 95% Cls. *Clinically significant value. (B) Dysmenorrhea and non-menstrual pelvic pain at 6 months (mean ± 95% CI). Error bars represent 95% Cls. *Clinically significant value. ABT: add-back therapy; LGX: linzagolix; OR: odds ratio; PBO: placebo.